Italian news outlets are reporting promising results from a Phase 3 trial of Moderna's personalized mRNA vaccine designed to prevent melanoma recurrence. According to Il Fatto Quotidiano, the positive data sent Moderna's stock price soaring on the stock market.
The vaccine, developed jointly with Merck, uses the same mRNA technology employed in Covid-19 shots, but is customized to each patient's tumor, as reported by Corriere della Sera. Sky TG24 confirmed that the experimental treatment cleared the Phase 3 testing hurdle.
ANSA, the Italian national wire service, described the drug as a success against melanoma and noted Moderna's strong performance on Wall Street following the announcement. Mondosanità, an Italian health publication, highlighted that the vaccine was built around the patient's own tumor, marking a personalized approach to cancer therapy.
The trial results, published on Wednesday, August 19, 2026, represent a significant step forward in the fight against melanoma, a potentially deadly form of skin cancer. The personalized nature of the vaccine means each dose is tailored to the specific genetic mutations of an individual's tumor, potentially making the immune response more targeted and effective.
While the reports describe the outcomes as positive and promising, the full data from the Phase 3 trial has not yet been made public in the articles cited. The collaboration between Moderna and Merck has been closely watched by the oncology community since the vaccine's early-stage trials showed encouraging signals.
What to watch next: whether regulators will request additional data or move toward approval applications based on these Phase 3 findings.
